Bioretec Ltd Business Review Q1 2026

Bioretec Ltd has reported a net sales figure of EUR 1.2 million for Q1 2026, reflecting early traction from their renewed operational and commercial strategy initiated in the second half of 2025. The company has seen substantial year-over-year growth in both the U.S. (449%) and Europe (203.3%). Adjusted sales margins have improved, and efforts to expand distribution channels and diversify customer bases are underway. CEO Sarah van Hellenberg Hubar-Fisher highlighted the launch of several initiatives aimed at enhancing market presence and stakeholder engagement as part of their strategy focusing on commercial robustness and innovation.